STAAR Surgical Company (STAA) - 10-K Summary
Business Context and Reporting Period
Company: STAAR Surgical Company
Filing Type: Form 10-K (Annual Report)
Period Ended: January 2, 2009
Business Overview: STAAR develops, manufactures, and sells intraocular lenses (IOLs) for cataract surgery and implantable Collamer lenses (ICLs) for refractive surgery. The company operates globally with manufacturing facilities in the U.S., Switzerland, and Japan. In early fiscal 2008, STAAR acquired the remaining 50% interest in its Japanese joint venture, Canon Staar, renaming it STAAR Japan, Inc.
Key Financial Metrics (Fiscal Year 2008)
| Metric | 2008 (Actual) | 2007 (Prior Year) |
|---|---|---|
| Net Sales | $74.9 million | $59.4 million |
| Gross Profit | $40.1 million (53.6% margin) | $29.3 million (49.3% margin) |
| Operating Loss | $(20.4) million | $(14.1) million |
| Net Loss | $(23.2) million | $(16.0) million |
| Loss Per Share (Basic/Diluted) | $(0.79) | $(0.57) |
| Cash and Cash Equivalents (End of Period) | $5.0 million | $10.9 million |
| Working Capital | $10.8 million | $21.0 million |
| Accumulated Deficit | $(125.9) million | $(102.7) million |
Debt: The company holds a $5.0 million Senior Promissory Note with Broadwood Partners, L.P. (7% interest) and a line of credit in Japan with approximately $2.2 million outstanding.
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 26.2% to $74.9 million, driven primarily by the consolidation of STAAR Japan (contributing $12.2 million in IOL sales) and growth in ICL sales (up 24.1% globally).
- U.S. Market Decline: Despite global growth, U.S. net sales decreased 4.0% due to a 16% decline in IOL sales, partially offset by an 18% increase in U.S. ICL sales.
- Expense Increases: Operating expenses rose significantly due to the consolidation of STAAR Japan and substantial legal costs associated with defending lawsuits from former sales representatives.
- Unusual Items: The 2008 results include a $4.9 million loss related to a jury verdict in Parallax Medical Systems, Inc. v. STAAR Surgical Company (rendered March 2, 2009, but accrued in Q4 2008) and a $3.85 million loss on the settlement of a pre-existing distribution arrangement related to the STAAR Japan acquisition.
Guidance, Outlook, Risks, and Contingencies
Going Concern Warning: The independent auditors have issued an explanatory paragraph expressing substantial doubt about the company's ability to continue as a going concern. This is due to recurring losses, negative cash flows, and the $4.9 million judgment against the company which exceeds current capital resources.
Legal Contingencies:
- Parallax Judgment: A $4.9 million judgment ($2.2M compensatory, $2.7M punitive) was entered March 23, 2009. Execution is stayed for approximately three months pending appeal. STAAR intends to appeal but lacks the cash to post a bond or satisfy the judgment without additional financing.
- Moody Litigation: A similar lawsuit (Moody v. STAAR) is scheduled for trial in May 2009, seeking $32 million in damages. The outcome is uncertain.
- Debt Default Risk: The Parallax judgment could trigger an event of default under the Broadwood Note, potentially accelerating the $5 million debt and increasing interest rates to 20%. A temporary waiver agreement was signed on April 2, 2009.
Regulatory Risks:
- TICL Approval: FDA review of the Toric ICL (TICL) application is on "integrity hold" pending resolution of clinical oversight deficiencies. Approval is critical for U.S. refractive growth.
- FDA Inspections: Recent inspections resulted in Form 483 observations, though the company believes it is substantially compliant.
Outlook: Management expects to generate positive cash flow from operations in 2009 if trends continue. Strategic goals include increasing ICL market share, shifting to higher-margin aspheric IOLs, and securing regulatory approvals. However, the company expects to seek additional equity or debt financing to meet working capital needs and litigation costs.
Key Facts for Investor Verification
- Liquidity Crisis: Verify the company's ability to secure financing to satisfy the $4.9 million Parallax judgment or post an appeal bond before the court stay expires (approx. 3 months from judgment).
- Debt Covenants: Confirm the status of the Temporary Waiver Agreement with Broadwood Partners and whether the Parallax judgment has triggered a default that could accelerate the $5 million note.
- U.S. Sales Trend: Monitor whether the restructured U.S. sales force and new aspheric IOL products can reverse the long-term decline in U.S. cataract (IOL) sales.
- Regulatory Status: Track the resolution of the FDA "integrity hold" on the TICL application, as U.S. approval is a primary growth driver.
- Moody Litigation: Assess the potential financial impact of the pending Moody trial, which could result in damages similar to or greater than the Parallax verdict.